An anonymous director reports

AVRICORE HEALTH ACHIEVES MILESTONES AND OUTLINES UK EXPANSION ROADMAP FOR HEALTHTAB™ PLATFORM

Avricore Health Inc.'s HealthTab has now screened more than 3,500 patients in community pharmacies across northeast and north-central London. During an initial one-month pilot of HbA1c testing for diabetes screening, the company completed 2,295 HbA1c tests across 57 locations, achieving a monthly per-location average 10 times higher than previously achieved in Canada.

Expansion road map

The company has published The Path Forward, a strategic update outlining the company's United Kingdom expansion strategy for its HealthTab point-of-care testing platform. The presentation is now available on the company's website.

The update outlines Avricore's progression from NHS-linked pilot programs in London toward broader regional and national expansion across England, supported by clinical outcomes, independent evaluation and growing institutional support.

U.K. program milestones

HealthTab has gained meaningful traction within the NHS, including the screening of more than 3,500 patients in community pharmacies across northeast and north-central London through a collaboration with Barts Health NHS Trust. In an initial lipid-screening cohort of 556 patients, approximately one in five was identified as having elevated cardiovascular risk.

The program has been independently evaluated by UCLPartners and has received attention from NHS England's chief pharmaceutical officer, as well as coverage by BBC National News. In addition, the British Heart Foundation, awarded a $385,000 grant to Barts Health, supporting an Inclisiran secondary-prevention pilot within the pharmacy network featuring HealthTab.

Expanding test menu and revenue model

HealthTab is continuing to expand its test menu within the NHS network. HbA1c testing for diabetes screening launched in Q1 2026, and UACR kidney function testing is planned for Q3 2026. In the first month of HbA1c availability, the network completed 2,295 tests in total across 57 pilot locations, approaching the approximately 3,000 tests per month average previously achieved across more than 700 locations in Canada.

The company expects current pilots to expand to more than 100 pharmacy sites in Q2 2026, with monthly subscription revenue expected to begin in the second half of 2026.

The path forward presentation also outlines a phased growth road map targeting 500 or more active U.K. locations by mid-2027, within a longer-term addressable market of more than 10,000 community pharmacies across 42 NHS England integrated care boards. The company currently has 700 analyzers staged and available for deployment from its London office.

Strategic context

Avricore reported 2024 revenue of $4.79-million, representing 37-per-cent year-over-year growth, alongside 56-per-cent gross profit growth. Two thousand twenty-five was a transition year, during which the company shifted its focus to the U.K. NHS market. The company is now focused on scaling its U.K. platform through NHS commissioning pathways and is targeting a return to profitability by Q3 2027.

Beginning in September, 2026, all newly qualified pharmacists in England will graduate as independent prescribers, a regulatory shift that further strengthens the clinical role of community pharmacy and supports the broader adoption of point-of-care testing infrastructure such as HealthTab.

Shareholders and prospective investors are encouraged to review the full presentation.

HealthTab at the core of scalable, integrated POCT

HealthTab is a complete, turnkey solution for community-based POCT networks, combining best-in-class instruments, cloud software, standardized workflows, and comprehensive training and support. At its centre is a secure, cloud-based platform that seamlessly connects point-of-care analyzers, patient results and QC (quality control) data into a unified digital infrastructure for distributed testing environments.

This fully integrated approach ensures quality-assured testing, consistent data capture across all locations and real-time analytics for public health reporting and performance monitoring, while significantly reducing implementation complexity for participating sites.

Commitment to quality and accuracy

HealthTab is designed to meet the highest standards of analytical performance and reliability. Through its partnership with CEQAL Inc., a world-leading reference method laboratory and member of the CDC Cholesterol Reference Method Laboratory Network (CRMLN), HealthTab operates a comprehensive quality management program that mirrors the rigour of accredited clinical laboratories.

The program includes centralized lot monitoring of reagents, internal quality control procedures, regular external quality assessment (EQA) events, and expert oversight services to support the accuracy, consistency and traceability of results to internationally recognized reference standards across participating sites.

About Avricore Health Inc.

Avricore Health is a pharmacy service innovator focused on acquiring and developing early stage technologies aimed at advancing pharmacy practice and patient care. Through its flagship offering HealthTab, a wholly owned subsidiary, the company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.

We seek Safe Harbor.